AusperBio’s AHB‑137 enters final testing phase in HBeAg-negative chronic hepatitis B patients

By on    Pharma & Biotech  

AusperBio’s AHB‑137 enters final testing phase in HBeAg-negative chronic hepatitis B patients

AusperBio Therapeutics has completed patient enrollment in its Phase III AUSHINE trial evaluating AHB‑137 for the treatment of HBeAg-negative chronic hepatitis B. The randomized, double-blind, multicenter study, launched in China under regulatory clearance from the Center for Drug Evaluation, surpassed its initial enrollment goal with over 570 patients enrolled within five months. AHB‑137 is being […]

Could AHB-137 set a new benchmark for HBV cure rates? Insights from AusperBio’s 24-week monotherapy trial

By on    Pharma & Biotech  

Could AHB-137 set a new benchmark for HBV cure rates? Insights from AusperBio’s 24-week monotherapy trial

AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s […]